STAAR Surgical (NASDAQ:STAA) Upgraded to “Strong-Buy” at Zacks Research

STAAR Surgical (NASDAQ:STAA) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

STAA has been the topic of several other reports. Wells Fargo & Company raised their target price on STAAR Surgical from $16.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday, May 15th. UBS Group initiated coverage on STAAR Surgical in a report on Tuesday, July 28th. They issued a “sell” rating and a $20.00 price target for the company. Stifel Nicolaus increased their price objective on shares of STAAR Surgical from $18.00 to $31.00 and gave the company a “hold” rating in a research report on Thursday, May 14th. Mizuho lifted their price objective on shares of STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Finally, Wedbush restated an “outperform” rating and issued a $40.00 target price on shares of STAAR Surgical in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, STAAR Surgical has a consensus rating of “Hold” and an average target price of $26.94.

STAAR Surgical Stock Performance

NASDAQ:STAA opened at $22.86 on Tuesday. The firm’s fifty day simple moving average is $27.43 and its 200 day simple moving average is $23.95. The company has a current ratio of 5.12, a quick ratio of 4.31 and a debt-to-equity ratio of 0.09. STAAR Surgical has a twelve month low of $15.59 and a twelve month high of $35.87. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -53.16 and a beta of 1.26.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, beating the consensus estimate of $0.05 by $0.05. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The company had revenue of $93.52 million for the quarter, compared to analyst estimates of $78.72 million. During the same period last year, the company posted ($1.10) earnings per share. The firm’s revenue was up 119.6% compared to the same quarter last year. As a group, equities research analysts expect that STAAR Surgical will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On STAAR Surgical

Several hedge funds and other institutional investors have recently bought and sold shares of STAA. Tudor Investment Corp ET AL acquired a new stake in STAAR Surgical in the third quarter valued at $4,113,000. GSA Capital Partners LLP acquired a new position in STAAR Surgical during the 4th quarter worth $910,000. UBS Group AG grew its holdings in STAAR Surgical by 39.2% during the 4th quarter. UBS Group AG now owns 327,852 shares of the medical instruments supplier’s stock worth $7,570,000 after acquiring an additional 92,321 shares in the last quarter. American Capital Management Inc. increased its position in shares of STAAR Surgical by 18.7% in the 1st quarter. American Capital Management Inc. now owns 878,035 shares of the medical instruments supplier’s stock worth $16,419,000 after purchasing an additional 138,499 shares during the last quarter. Finally, Crcm LP acquired a new stake in shares of STAAR Surgical in the 1st quarter valued at about $1,870,000. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting STAAR Surgical

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Wedbush maintained its “Outperform” rating and set a $40 price target, implying substantial upside from the stock’s recent level. The bullish view may reflect confidence in STAAR Surgical’s earnings growth and demand for its implantable contact lenses. Benzinga analyst rating report
• Positive Sentiment: Zacks upgraded STAAR Surgical to Rank #1, or “Strong Buy,” citing improving earnings prospects. The upgrade could attract momentum-oriented investors and provide near-term support for STAA. Zacks Strong Buy upgrade
• Positive Sentiment: Warren Foust has been named president and chief executive officer. Foust previously served as STAAR Surgical’s chief operating officer and has experience at Johnson & Johnson, suggesting leadership continuity along with relevant industry expertise. Warren Foust named president and CEO STAAR Surgical appoints new CEO
• Neutral Sentiment: STAAR Surgical will release second-quarter 2026 results on August 12. The upcoming earnings call is the next major catalyst, with investors likely focused on procedure growth, sales momentum, margins and management’s outlook. STAAR Surgical second-quarter earnings call announcement
• Neutral Sentiment: Analysts collectively rate STAA “Hold.” This consensus is less bullish than the latest Zacks and Wedbush calls, indicating that valuation, execution or upcoming earnings risks remain concerns. STAAR Surgical analyst consensus

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.